Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $160.46M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.27M
Average 0.16M
Returns on capital
Oramed Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
32.1%
avg -27.0%
ROIC
-6.0%
avg -23.8%
ROA
27.7%
avg -17.9%
Analysis
ROE is currently the strongest return metric at 32.1% versus its period average of -27.0%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nadav Kidron | President, Chief Executive Officer & Executive Chairman | USD 1.07M | 52 | 4.77M | 11.65% |
Miriam Kidron | Chief Scientific Officer & Director | USD 760.35K | 86 | 1.91M | 4.66% |
Joshua Hexter | Chief Operating & Business Officer | USD 583.33K | 56 | 1.69M | 4.12% |
Avraham Gabay | Chief Financial Officer, Treasurer & Secretary | USD 303.07K | 41 | 1.22M | 2.98% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$1.17M
Net Transaction Value
−$1.17M
Net selling
Most Active
Gabay Avraham
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | Gabay Avraham Direct | Sell | $90.2K$90,200.00 |
| Oct 1, 26Oct 1, 2026 | Hexter Joshua Direct | Sell | $135.3K$135,330.00 |
| Jul 1, 26Jul 1, 2026 | Gabay Avraham Direct | Sell | $330.7K$330,743.56 |
| Jul 1, 26Jul 1, 2026 | Hexter Joshua Direct | Sell | $611.4K$611,431.00 |
Summary
Insiders reported 0 buys worth $0.00 and 4 sells worth $1.17M over the last 12 months. That adds up to net selling of $1.17M. Gabay Avraham was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -9.6% | -37.6% (2yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -9.6% over three years. Forward estimates point to Revenue at -37.6% (2yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Oramed Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ORMP's management, answered from reported figures.
Who manages ORMP?
Oramed Pharmaceuticals Inc. (ORMP) lists 4 active executives. The top listed executive is Joshua Hexter, Chief Operating & Business Officer.
Are ORMP insiders buying or selling?
Recent insider activity shows net selling of $7.89M.
Continue the stock analysis
Jump to another research area for this company.